Recce Pharmaceuticals Ltd

Pharmaceutical ManufacturingNew South Wales, Australia11-50 Employees

Recce Pharmaceuticals Ltd is an Australia-based pharmaceutical company focused on developing a new class of synthetic anti-infectives to address antibiotic-resistant bacteria and emerging viral pathogens. Its pipeline includes RECCE 327 for serious infections (administered intravenously or topically), RECCE 435 for bacterial infections (orally), and RECCE 529 for viral infections. Regulatory designations underscore its progress, with the FDA granting R327 Qualified Infectious Disease Product status and Fast Track, and the WHO listing the three compounds among antibacterial products in development for priority pathogens. Recce also owns automated manufacturing that supports its ongoing clinical trials.

Headquartered in Sydney, New South Wales, the company operates in the pharmaceutical manufacturing sector and employs a relatively small team. In February 2026 it announced a Cooperative Research and Development Agreement with the US Army Institute of Surgical Research, reflecting collaboration with a government research partner.

Sign up for free to view info

Email Format Employee directory